November 25, 2016 – Raleigh, NC

MAA Laboratories has appointed Mr. Pieter de Ridder as Chief Business Officer.  Mr. Pieter Ridder has over 20 years of global leadership experience in business development and commercial operations of generics and biotechnology companies. 

Prior to joining MAA Laboratories, Mr. Ridder served as the President of Glycan Therapeutics, an emerging biotech company specialized in glycobiology based on a proprietary chemoenzymatic oligosaccharide synthesis platform. Previously, he was Vice President Sales and Marketing and Chief Commercial Officer for Synthon, a global specialty pharmaceutical company focused on the development, manufacturing and marketing of generics and branded biopharmaceutical products. Mr. Ridder has a proven track record of driving growth through rigorous planning and execution of well thought-out strategies in established and startup companies. He has extensive experience in commercial strategy, sales, business development, and licensing of pharmaceutical products in North America and Europe. Mr. de Ridder holds an MBA from Duke University in Durham, NC.

About MAA Laboratories Inc.
MAA Laboratories Inc. is a specialty pharmaceutical company located in the Research Triangle Park region of North Carolina. MAA has developed the NanoCont^TM drug development platform as a broadly applicable solution for addressing a variety of drug delivery and development challenges. Our company is dedicated to using the NanoCont^TM technology to create advanced medicines that improve patients’ lives by addressing unmet clinical needs in a variety of therapeutic areas, including oncology, neurological, and cardiovascular diseases.

The NanoCont^TM drug development platform
MAA Laboratories’ NanoCont^TM technology is a broadly applicable drug development solution for improving the clinical performance of poorly soluble pharmaceuticals. Aspects of drug performance that can be improved by the NanonCont^TM technology include: increased therapeutic efficiency, enhanced targeted drug delivery, elimination of food effects, increased oral bioavailability, reduced intra- and inter-patient variability, and/or mitigated undesirable side effects. This technology can be used to reformulate marketed products in a manner that resolves known drug performance liabilities and creates new intellectual property protection. For investigational compounds, the NanoCont^TM technology can be used to overcome hurdles related to low solubility and poor bioavailability to ensure consistent dosing and facilitating the development of promising pipeline compounds.

Contact MAA Laboratories
For inquiries related to product licensing and development partnerships, please contact our business development team at BD@maalaboratories.com.

For press and other inquiries, please contact:

Corporate Office
MAA Laboratories, Inc.
400 Park Offices Drive
Suite# 214
Durham, NC 27709
United States of America
Email: info@maalaboratories.com
Phone: 919.271.7868